Recent Press Releases

AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)

- Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases - HS, a chronic, immune-mediated skin...

Takeda reports top line results in line with guidance, with underlying growth of +2.8%

EPS affected by one-time charges in FY2014 Back to profitable growth from FY2015 onward Operational guidance met Underlying revenue +2.8% year-over-year, in line with guidance (reported...

Amgen Announces Voting Results of Annual Meeting of Stockholders

THOUSAND OAKS, Calif., May 14, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced voting results

Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies

INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical

Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio

THOUSAND OAKS, Calif., May 13, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data

Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave Collaboration with Takeda Pharmaceuticals

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes...

Biogen Names Matt Griffiths as Chief Information Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Matt Griffiths as senior vice president and chief information officer (CIO). He will report to the...

Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016

INDIANAPOLIS, May 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has comm

Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer

Ten Champions Will Join Cancer Survivor Joan Lunden at the Overall Finish of the 10th Edition of the Amgen Tour of California


Baxter BioScience to Expand Global Oncology Footprint with Acquisition of Oncaspar® Portfolio for Leukemia

Company gains an oncology infrastructure, marketed biologic and investigational treatment New portfolio strengthens leadership in rare and orphan diseases for Baxter BioScience, expected to...

Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV

RARITAN, N.J., May 11, 2015 /PRNewswire/ -- Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of children living...

AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting

NORTH CHICAGO, Ill., May 11, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced 17 abstracts from studies of the company's oncology pipeline are being presented at the 51st Annual Meeting of the...

Universal Health Services, Inc. to Present at the Bank of America Merrill Lynch Healthcare Conference

KING OF PRUSSIA, Pa., May 11, 2015 /PRNewswire/ -- Universal Health Services, Inc.

Roche Receives FDA Approval for cobas® KRAS Mutation Test

Molecular PCR test identifies KRAS mutations to aid in determining therapy for metastatic colorectal cancer


Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly

Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society

Data Evaluating Safety and Efficacy of AMG 334 Provides New Insights Into Preventive Treatment of Migraine


Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

Adjusted EBITDA Increases 107% to $1.8 Billion in First Quarter 2015 -- -- Robust Performance Across Global Businesses -- -- Broad-Based Strength from Allergan; Contributes $258 Million in...

Endo Reports First Quarter 2015 Financial Results

DUBLIN, May 11, 2015 /PRNewswire/ -- First quarter revenues of $714 million First quarter reported $0.85 diluted (GAAP) EPS from continuing operations and $1.17 adjusted diluted EPS from...